Tumor−derived CXCL12 and CCL5 are known to recruit suppressive myeloid and regulatory T cells, promote tumor growth, and stimulate neoangiogenesis (44, 45), whereas TGF−β directly attenuates CD8+ T cell cytotoxicity and drives exhaustion in chronic inflammatory contexts (46). This evidence concerns the gene CCL5 and neoplasm.